Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mifepristone - Corcept Therapeutics

Drug Profile

Mifepristone - Corcept Therapeutics

Alternative Names: C 1073; Corlux; Corluxin; Korlym; Mifegyne; Mifeprex; RU 38486; RU-486

Latest Information Update: 26 Dec 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roussel Uclaf; Stanford University
  • Developer Corcept Therapeutics; Danco Laboratories; Population Council (USA); pSivida; Stanford University; University of Chicago
  • Class Abortifacients; Antidementias; Antiprogestogens; Antipsychotics; Antivirals; Dimethylamines; Estrenes; Eye disorder therapies; Oral contraceptives; Small molecules; Smoking cessation therapies
  • Mechanism of Action Glucocorticoid receptor antagonists; Progesterone receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cushing syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cushing syndrome; Induced abortion
  • Phase II Alcoholism; Breast cancer
  • Phase I/II Prostate cancer
  • No development reported Central serous chorioretinopathy; Non-small cell lung cancer; Smoking withdrawal
  • Discontinued Alzheimer's disease; Obesity; Ocular hypertension; Psychotic affective disorders

Most Recent Events

  • 26 Dec 2022 Phase II development for Breast cancer and Alcoholism is ongoing in USA (Corcept therapeutics pipeline, December 2022)
  • 26 Dec 2022 No development reported - Phase-II for Central serous chorioretinopathy in USA (PO)
  • 26 Dec 2022 No development reported - Phase-II for Non-small cell lung cancer (In the elderly, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater, In adults) in USA (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top